Journal
IMMUNOLOGIC RESEARCH
Volume 41, Issue 1, Pages 56-78Publisher
HUMANA PRESS INC
DOI: 10.1007/s12026-007-0043-x
Keywords
genetic variation; human major histocompatibility complex; HLA matching; immune response genes; single nucleotide polymorphisms (SNPs)
Categories
Funding
- NCI NIH HHS [CA18029, CA015704] Funding Source: Medline
- NHLBI NIH HHS [K23HL69860, HL087690] Funding Source: Medline
- NIAID NIH HHS [AI33484] Funding Source: Medline
- PHS HHS [A149213] Funding Source: Medline
Ask authors/readers for more resources
Successful outcome following hematopoietic stem cell transplantation (HSCT) is ultimately determined by the ability to achieve sustained engraftment and immune reconstitution, control of graft-versus-host disease (GVHD), and in patients with hematological malignancy the complete eradication of abnormal or malignant cells. GVHD, which can be a serious and fatal complication, is an immune reaction that is initiated by donor T cells in response to recipient alloantigens. Genetic variation in both patient and donor can significantly affect transplant outcome by causing disparity for transplant antigens, and by altering the function of immune response genes that control cellular activation and inflammation. Genetic variation can modulate the intensity of the alloimmune response, the risk of transplant-related organ toxicity and mortality, and may also affect the development of tolerance and the reconstitution of the immune system following HSCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available